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Systemic sclerosis is characterized by ¢brosis and
systemic autoimmunity; however, roles of autoantibo-
dies in the development of ¢brosis remain unknown in
systemic sclerosis.The net accumulation of extracellular
matrix is dependent on the balance between the synthesis
and degradation of extracellular matrix components,
the latter process regulated by matrix metallo-
proteinases. Matrix metalloproteinase-1 (interstitial
collagenase-1) can initiate degradation of collagen types
I^III that are major extracellular matrix constituents in
a¡ected skin of systemic sclerosis. In this study, we
tested the hypothesis that systemic autoimmunity in
systemic sclerosis induced anti-matrix metalloprotei-
nase-1 autoantibodies that inhibited matrix metallo-
proteinase-1 activity, resulting in collagen accum-
ulation. Enzyme-linked immunosorbent assay using
human recombinant matrix metalloproteinase-1 re-
vealed that IgG anti-matrix metalloproteinase-1 auto-
antibody levels were signi¢cantly elevated in sera from
patients with systemic sclerosis, but not patients with
active systemic lupus erythematosus or dermatomyosi-
tis, relative to normal controls. IgG anti-matrix
metalloproteinase-1 autoantibody levels were signi¢-
cantly higher in patients with di¡use cutaneous sys-
temic sclerosis than those found in patients with
limited cutaneous systemic sclerosis. Furthermore, IgG
anti-matrix metalloproteinase-1 antibody levels signi¢-
cantly correlated with the extent of ¢brosis in the skin,
lung, and renal blood vessels. The presence of IgG anti-
matrix metalloproteinase-1 autoantibody in sera from
systemic sclerosis patients was con¢rmed by immuno-
blotting analysis. Remarkably, IgG anti-matrix metal-
loproteinase-1 autoantibody in sera from systemic
sclerosis patients inhibited matrix metalloproteinase-1
collagenase activity. Collectively, the results of this
study suggest that anti-matrix metalloproteinase-1
autoantibody contributes to the development of ¢brosis
by inhibiting matrix metalloproteinase-1 collagenase
activity and reducing the extracellular matrix turnover
and suggest that the presence of anti-matrix metallo-
proteinase-1 autoantibody in systemic sclerosis is the
link between systemic autoimmunity and ¢brosis. Key
words: autoimmunity/collagenase/extracellular matrix/¢brosis.
J Invest Dermatol 120:542 ^547, 2003
S
ystemic sclerosis (SSc) is a connective tissue disorder that
is characterized by ¢brosis and vascular changes in the
skin and other visceral organs, with an autoimmune
background. The central event in the pathogenesis of
SSc is an abnormal accumulation of extracellular matrix
(ECM) components, predominantly types I and III collagens
(Lovell et al, 1979; Jimenez et al, 1996). Consistently, ¢broblasts cul-
tured from the a¡ected skin of patients with SSc display a mor-
phologically activated phenotype producing increased amounts
of various connective tissue components, mainly of type I col-
lagen (LeRoy, 1974; Jimenez et al, 1996). Various cytokines
or growth factors that are produced partly by in£ammatory cells
in¢ltrating the a¡ected tissues may be involved in the initiation
or development of ¢brotic process (Jimenez et al, 1996; Sato, 1999).
The net accumulation of ECM in tissue is dependent on the
balance between the synthesis and the degradation of ECM com-
ponents. The latter process is regulated by matrix metalloprotei-
nases (MMP), a family of zinc-dependent endopeptidases that
collectively can digest all ECM components (K<h<ri and Saarialho-
Kere, 1997; Nagase andWoessner, 1999). MMP-1 (interstitial col-
lagenase-1) is able to initiate degradation of interstitial collagen
types I^III that are major constituents of the ECM in both nor-
mal skin and a¡ected skin of SSc (Lovell et al, 1979; Jimenez
et al, 1996; K<h<ri and Saarialho-Kere, 1997). The expression
of MMP is induced in response to exogenous signals, such as var-
ious cytokines or growth factors, cell^matrix interactions, and
cell^cell interactions (K<h<ri and Saarialho-Kere, 1997; Nagase
and Woessner, 1999). To prevent excessive function of MMP, the
proteolytic activity of MMP is inhibited by nonspeci¢c inhibi-
tors, including a2-macroglobulin, as well as speci¢c inhibitors
of tissue inhibitors of metalloproteinases (TIMP) (Gomez et al,
1997; K<h<ri and Saarialho-Kere, 1997; Nagase and Woessner,
1999). Thus, the balance between MMP and TIMP levels governs
connective tissue homeostasis.
The abnormal regulation of MMP and TIMP expression has
been reported in SSc. Takeda et al (1994) have shown that SSc
¢broblasts exhibit decreases in MMP-1 activity and production
compared with normal ¢broblasts. By contrast, another recent
study has shown that ¢broblasts from patients with early stage
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SSc display higher levels of MMP-1 and MMP-3 than those from
normal individuals, whereas levels of MMP-1 and MMP-3
decrease in ¢broblasts from SSc patients with mid-stage SSc
(Kuroda and Shinkai, 1997). Expression levels of TIMP-1, -2,
and -3 by ¢broblasts from SSc patients are increased relative to
normal ¢broblasts (Kirk et al, 1995; Kikuchi et al, 1997; Kuroda
and Shinkai, 1997; Mattila et al, 1998). In addition, elevated serum
levels of TIMP-1 or TIMP-2 have been reported in patients with
SSc in correlation with disease activity (Kikuchi et al, 1995;
Yazawa et al, 2000; Young-Min et al, 2001). Thus, the altered
balance between MMP and their inhibitors appears to play an
important part in the development of ¢brosis in SSc.
Systemic autoimmunity is another central feature of SSc as
anti-nuclear antibodies are detected in more than 90% of patients
with SSc (Okano, 1996); however, roles of these autoantibodies in
disease expression, such as ¢brosis, remains unknown in SSc.We
hypothesized that autoimmune background in SSc induced
pathogenic autoantibodies that inhibited MMP-1 activity and
thereby contributed to the collagen accumulation. To test this
possibility, the presence or levels of anti-MMP-1 antibodies, their
clinical correlation, and their functional signi¢cance were investi-
gated in this study. The results of this study suggest that anti-
MMP-1 autoantibodies detected in patients with SSc play a part
in the development of ¢brosis by directly inhibiting MMP-1
collagenase activity.
MATERIALS AND METHODS
Serum samples Serum samples were obtained from 57 Japanese patients
with SSc (51 females and six males). All patients ful¢lled the criteria
proposed by the American College of Rheumatology (Subcommittee for
Scleroderma Criteria of the American Rheumatism Association Diagnostic
and Theraputic Criteria Committee 1980). These patients were grouped
according to the classi¢cation system proposed by LeRoy et al (1988): 33
patients (32 females and one male) had limited cutaneous SSc (lSSc) and
24 patients (¢ve females and 19 males) had di¡use cutaneous SSc (dSSc).
The age of patients with SSc (mean7SD) was 44716. Patients with dSSc
were 42719 y old, whereas those with lSSc were 46715 y old. The disease
duration of patients with lSSc and dSSc was 7.778.7 and 4.776.7 y,
respectively. None of the SSc patients were treated with steroids,
D-penicillamine, or immunosuppressive therapy. Anti-nuclear antibodies
were determined by indirect immuno£uorescence using HEp-2 cells as
substrate and autoantibody speci¢cities were further assessed by enzyme-
linked immunosorbent assay (ELISA) speci¢c for antibodies against
topoisomerase I, centromere, or U1RNP. Anti-topoisomerase I antibody
was positive for 23 (dSSc, 18 and lSSc, ¢ve), anti-centromere antibody for
24 (dSSc, one and lSSc, 23), and anti-U1RNP antibody for three (dSSc,
one and lSSc, two). Seven patients (dSSc, four and lSSc, three) had anti-
nuclear antibodies, but their speci¢cities were not identi¢ed by
autoantibody-speci¢c ELISA. Of these seven patients, two patients had
anti-RNA polymerases I and III antibody and anti-U3RNP antibody by
immunoprecipitation, respectively; however, autoantibody speci¢cities in the
remaining ¢ve patients were not still identi¢ed by immunoprecipitation.
Nineteen patients with systemic lupus erythematosus (SLE), who ful¢lled
the American College of Rheumatology criteria (Tan et al, 1982), were also
examined as disease control in this study. These patients had active SLE as
determined by the SLE Disease Activity Index (Bombardier et al, 1992). In
addition, 16 patients with dermatomyositis that ful¢lled Bohan and Peter
criteria (Bohan and Peter, 1975a; Bohan and Peter, 1975b) were included.
Age- and sex-matched 30 Japanese healthy persons (three males and 27
females; age, 43710 y) were used as normal controls. Fresh venous blood
samples were centrifuged shortly after clot formation. All samples were
stored at ^701C prior to use.
Clinical assessment Complete medical histories, physical examinations,
and laboratory tests were conducted for all patients. Skin score was
measured by scoring technique of the modi¢ed Rodnan total skin
thickness score (modi¢ed Rodnan TSS) (Clements et al, 1993). The 17
anatomic areas were rated as 0 (normal skin thickness), 1þ (mild but
de¢nite skin thickening), 2þ (moderate skin thickening), and 3þ (severe
skin thickening) and the modi¢ed Rodnan TSS was derived by
summation of the scores from all 17 areas (range 0^51). Organ system
involvement was de¢ned as described previously (Steen et al, 1988; Sato
et al, 1994): lung¼bibasilar ¢brosis on chest radiography and high-
resolution computed tomography; esophagus¼ hypomotility shown by
barium radiography; joint¼ in£ammatory polyarthralgias or arthritis;
heart¼ pericarditis, congestive heart failure, or arrhythmias requiring
treatment; kidney¼malignant hypertension and rapidly progressive renal
failure without any other explanation; and muscle¼ proximal muscle
weakness and elevated serum creatine kinase. Renal vascular damage was
determined as a pulsatility index by color-£ow Doppler ultrasonography
of both kidneys (Warshauer et al, 1988; Nishijima et al, 2001). The
pulsatility index, which represents vascular impedance, was calculated as
A^B/mean, where A is the peak systolic frequency, B is the end diastolic
frequency, and the mean is the time-averaged frequency. The pulsatility
index was calculated as an average value obtained with eight waveforms
on the renal interlobar arteries of both kidneys. Pulmonary function test,
including vital capacity (VC) and di¡usion capacity for carbon monoxide
(DLco), was also tested.When the DLco andVC wereo75% ando80%,
respectively, of the predicted normal values, they were considered to be
abnormal. There were no patients with pulmonary hypertension without
pulmonary ¢brosis. The protocol was approved by the Kanazawa
University Graduate School of Medical Science and Kanazawa University
Hospital, and informed consent was obtained from all patients.
ELISA for anti-MMP-1 antibodies ELISA were conducted as
previously described (Sato et al, 2000). Ninety six-well plates were coated
with human recombinant MMP-1 (1 mg per ml; Techne Corp.,
Minneapolis, MN) at 41C overnight. The serum samples diluted to 1 : 100
were added to triplicate wells for 90 min at 201C. After washing, the
bound antibodies were detected with alkaline phosphatase-conjugated
goat anti-human IgG or IgM antibodies (Cappel, Durham, NC), using
p-nitrophenyl phosphate (Sigma-Aldrich, St Louis, MO) as substrate. The
optical density (OD) of the wells was subsequently determined. Relative
levels of autoantibodies were determined for each group of patients and
normal controls using pooled serum samples as previously described (Sato
et al, 2000). The sera were diluted at log intervals (1 : 10^1 : 105) and assessed
for relative autoantibody levels as above except the results were plotted as
OD vs dilution (log scale). The dilutions of sera giving half-maximal OD
values were determined by linear regression analysis, thus generating
arbitrary unit per milliliter values for comparison between sets of sera.
Immunoblotting Human recombinant MMP-1 (0.1 mg per lane;Techne
Corp.) was subjected to electrophoresis and electrotransferred to
nitrocellulose sheets. The nitrocellulose strips were incubated overnight
with serum samples diluted 1 : 50 and were then incubated for 1.5 h with
alkaline phosphatase-conjugated goat anti-human IgG antibody (Cappel).
Color was developed using an ampli¢ed alkaline phosphatase Immuno-
Blot assay kit (Bio-Rad Laboratories Inc., Hercules, CA). Ten SSc patients
positive for IgG anti-MMP-1 antibody by ELISA, nine SSc patients
positive for either anti-topoisomerase I antibody, anti-centromere
antibody, or anti-U1RNP antibody, but not for IgG anti-MMP-1
antibody by ELISA, and six healthy individuals were evaluated.
MMP-1 collagenase activity assay IgG was puri¢ed from serum
samples using magnetic beads coated with recombinant protein G
covalently coupled to the surface (Dynal Inc., Lake Success, NY). Final
IgG concentration was measured by spectrophotometer (Gene Quant II,
Amersham Biosciences Inc., Piscataway, NJ). MMP-1 collagenase activity
was determined by a collagenase activity kit (Chemicon International,
Inc., Temecula, CA), according to the manufacturer’s protocol. Brie£y, 4.5
ng of MMP-1 activated by p-aminophenylmercuric acetate was incubated
with 40 mg of puri¢ed IgG for 20 min at 201C. The enzymatic activity of
MMP-1 was measured using biotinylated bovine native collagen as
substrate. The cleaved biotinylated fragments of collagen by MMP-1 were
transferred to triplicate wells of biotin-binding 96-well microtiter plates
and detected by streptavidin-peroxidase complex and enzyme substrate.
The OD of the wells was subsequently determined. MMP-1 that was
activated by p-aminophenylmercuric acetate and untreated with IgG
served as positive control. Ten SSc patients positive for IgG anti-MMP-1
antibody by ELISA, 10 SSc patients positive for positive for either anti-
topoisomerase I antibody, anti-centromere antibody, or anti-U1RNP
antibody, but not for IgG anti-MMP-1 antibody by ELISA, and 10
healthy individuals were assessed.
Statistical analysis Statistical analysis was performed using the Mann^
Whitney U test for determining the level of signi¢cance of di¡erences
between sample means, Fisher’s exact probability test for comparison of
frequencies, and Bonferroni’s test for multiple comparisons. Spearman’s
rank correlation coe⁄cient was used to examine the relationship between
two continuous variables. po0.05 was considered statistically signi¢cant.
ANTI-MMP-1 AUTOANTIBODY IN SSC 543VOL. 120, NO. 4 APRIL 2003
RESULTS
Anti-MMP-1 autoantibody levels in SSc by ELISA The
presence and levels of anti-MMP-1 autoantibodies in serum
samples from patients with collagen diseases and normal
controls were assessed by ELISA (Fig 1). The dilution of sera
giving half-maximal OD values in ELISA was also determined
to generate arbitrary units per milliliter that could be directly
compared between patients and normal controls. Pooled sera
from patients with dSSc had mean IgG and IgM anti-MMP-1
antibody levels that were signi¢cantly 6.2-fold and 2.0-fold
higher than those found in normal controls (po0.0001 and
po0.05, respectively). Patients with lSSc exhibited mean IgG
anti-MMP-1 antibody levels that were signi¢cantly 56% higher
than those in normal controls (po0.05), but had almost normal
IgM levels of anti-MMP-1 antibody. IgG anti-MMP-1 antibody
levels in patients with dSSc were signi¢cantly increased
compared with patients with lSSc (po0.001), those with active
SLE (po0.0005), or those with dermatomyositis (po0.0005).
There were no signi¢cant di¡erences, however, in IgM anti-
MMP-1 antibody levels between patients with dSSc and those
with lSSc, SLE, or dermatomyositis. In total patients with SSc,
IgG anti-MMP-1 antibody levels were signi¢cantly higher than
those found in normal controls (po0.001), patients with SLE
(po0.05), or those with dermatomyositis (po0.01), whereas IgM
anti-MMP-1 antibody levels were similar for total patients with
SSc, normal controls, and patients with SLE or dermatomyositis.
IgG anti-MMP-1 antibody levels correlated positively with IgM
anti-MMP-1 antibody levels in total patients with SSc (r¼ 0.361,
po0.0001). IgG and IgM anti-MMP-1 antibody levels, however,
did not correlate with serum total IgG and IgM levels,
respectively (data not shown). In addition, IgG or IgM anti-
MMP-1 antibody levels were not associated with levels of other
autoantibodies, including antibodies against topoisomerase I,
centromere, and U1RNP (data not shown). Thus, IgG anti-
MMP-1 autoantibody levels were increased in SSc, especially
dSSc, but not in other collagen diseases, including SLE and
dermatomyositis.
Frequency of anti-MMP-1 antibody positivity and clinical
correlation in SSc Absorbance values higher than the
meanþ 2 SD (0.59 for IgG anti-MMP-1 antibody and 0.78 for
IgM anti-MMP-1 antibody) of the control serum samples were
considered positive in this study (Fig 1). IgG or IgM anti-MMP-
1 antibody was detected in 75% of patients with dSSc, whereas
only 30% of patients with lSSc were positive (Table I). In total
patients with SSc, IgG or IgM anti-MMP-1 antibody was found
in 49%. By contrast, anti-MMP-1 antibody was detected in only
one healthy individual (3%). In dSSc, all seven patients with IgM
anti-MMP-1 antibody were also positive for IgG anti-MMP-1
antibody, whereas the remaining 11 patients had IgG anti-MMP-
1 antibody alone. In lSSc, both IgM and IgG anti-MMP-1
antibodies were positive in one patient, IgM anti-MMP-1
antibody alone in ¢ve patients, and IgG anti-MMP-1 antibody
alone in four patients. IgG or IgM anti-MMP-1 antibody was
positive in 57% (13 of 23) of SSc patients with anti-
topoisomerase I antibody and 67% (two of three) of those with
anti-U1RNP antibody, whereas it was found in 38% (nine of 24)
of those with anti-centromere antibody. One patient with anti-
RNA polymerases I and III had IgG anti-MMP-1 antibody,
whereas one patient with anti-U3RNP antibody did not have
anti-MMP-1 antibody. Concerning clinical correlation, SSc
patients with IgG anti-MMP-1 antibody had lung ¢brosis more
frequently than those without IgG anti-MMP-1 antibody (14
of 23, 61% vs 10 of 34, 29%, po0.05). Frequency of IgG
anti-MMP-1 antibody positivity, however, was not associated
with the presence or absence of other organ involvement,
including joint, muscle, esophagus, kidney, and heart (data not
shown). Frequency of IgM anti-MMP-1 antibody positivity did
not correlate with the presence or absence of any organ
involvement (data not shown).
Then, the direct correlation of anti-MMP-1 antibody levels
with the extent of skin sclerosis, renal vascular damage, and
lung ¢brosis was assessed. IgG anti-MMP-1 antibody levels
correlated positively with the modi¢ed Rodnan TSS, the
semiquantitative measure of skin sclerosis (Clements et al, 1993)
(po0.0002; Fig 2A). Similarly, the positive association of IgG
anti-MMP-1 antibody levels with renal vascular resistance,
which was determined as the pulsatility index value in the renal
interlobar arteries by color-£ow Doppler scans (Warshauer et al,
1988; Nishijima et al, 2001), was observed (po0.001; Fig 2B).
Furthermore, IgG anti-MMP-1 antibody levels correlated
inversely with %DLco (po0.005; Fig 2C) or %VC (po0.01;
Fig 2D), both of which re£ect the severity of lung ¢brosis
(Silver, 1996). Any signi¢cant association of IgM anti-MMP-1
antibody levels with clinical parameters described above,
however, was not observed (data not shown). Thus, IgG anti-
MMP-1 antibody levels correlated with the extent of ¢brosis in
the skin, lung, and blood vessels.
Figure1. Anti-MMP-1 antibody levels were elevated in serum sam-
ples from patients with SSc, especially dSSc. IgG or IgM anti-MMP-1
antibody levels were determined by ELISA using human recombinant
MMP-1 in patients with lSSc, those with dSSc, those with SLE, those with
dermatomyositis, and normal controls (CTL). The short bar indicates the
mean value in each group. A broken line indicates the cut-o¡ value
(meanþ 2 SD of the control samples). Values in parenthesis represent the
dilutions of pooled sera giving half-maximal OD values in ELISA, which
were determined by linear regression analysis to generate arbitrary units
per milliliter that could be directly compared between each group of
patients and normal controls.
Table I. Frequency of anti-MMP-1 antibody positivity in col-
lagen diseases and normal controlsa
Anti-MMP-1 antibody
IgGb IgM IgG or IgM
SSc (n¼ 57) 23 (40) 13 (23) 28 (49)
lSSc (n¼ 33) 5 (15) 6 (18) 10 (30)
dSSc (n¼ 24) 18 (75) 7 (29) 18 (75)
SLE (n¼19) 1 (5) 2 (11) 3 (16)
Dermatomyositis (n¼16) 1 (5) 1 (6) 2 (13)
Normal (n¼ 30) 1 (3) 0 1 (3)
aValues are the number (%) of patients with anti-MMP-1 antibody that was
determined by ELISA using human recombinant MMP-1.
bIsotypes (IgG or IgM) of anti-MMP-1 antibody were determined using iso-
type-speci¢c anti-human immunoglobulin antibodies.
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Immunoblotting analysis for anti-MMP-1 antibody The
presence of anti-MMP-1 antibody was evaluated by
immunoblotting analysis using human recombinant MMP-1.
All tested serum samples from SSc patients positive for IgG
anti-MMP-1 antibody by ELISA exhibited reactivity with
MMP-1 (E 52 kDa) by immunoblotting (lanes 2^4, Fig 3). By
contrast, any reactivity with MMP-1 was not observed using
serum samples with either anti-topoisomerase I, anti-centromere
antibody, or anti-U1RNP antibody, but without IgG anti-MMP-
1 antibody by ELISA (lane 5 and data not shown). Furthermore,
serum samples from healthy individuals did not react with
MMP-1 (lane 6). Thus, the presence of anti-MMP-1 auto-
antibody in patients with SSc was con¢rmed by immuno-
blotting analysis.
Inhibition of MMP-1 collagenase activity by anti-MMP-1
antibody To determine the functional relevance of anti-MMP-
1 antibody in vivo, it was assessed whether anti-MMP-1
autoantibody was able to inhibit MMP-1 collagenase activity.
MMP-1 collagenase activity was determined using biotinylated
bovine native collagen as substrate. The amount of cleaved
biotinylated fragments of collagen by MMP-1 was measured
by ELISA. MMP-1 collagenase activity was not inhibited by
IgG isolated from healthy individuals (Fig 4). By contrast, IgG
isolated from serum samples of SSc patients positive for IgG
anti-MMP-1 antibody by ELISA signi¢cantly inhibited MMP-1
collagenase activity by 77% compared with normal control
(po0.001). This inhibitory activity was not due to the presence
of autoantibodies other than anti-MMP-1 antibody as MMP-1
collagenase activity was not inhibited by IgG isolated from
serum samples that contained autoantibodies against topo-
isomerase I, centromere, or U1RNP, but not IgG anti-MMP-1
antibody. Serum samples from lSSc patients positive for IgM
anti-MMP-1 antibody alone did not block MMP-1 activity
compared with sera from normal individuals (data not shown).
Thus, IgG anti-MMP-1 antibody from patients with SSc was
able to inhibit MMP-1 collagenase activity.
Figure 2. IgG anti-MMP-1 antibody levels correlated with the ex-
tent of ¢brosis in the skin, renal blood vessels, and lung in patients
with SSc.We correlated IgG anti-MMP-1 antibody levels (relative OD)
with modi¢ed Rodnan TSS (A), pulsatility index (B), %DLco (C), or
%VC (D). Anti-MMP-1 antibody levels were determined by ELISA using
human recombinant MMP-1. The extent of skin sclerosis was measured by
modi¢ed Rodnan TSS. The 17 anatomic areas were rated as 0 (normal),
1þ (mild skin thickening), 2þ (moderate), and 3þ (severe), and the mod-
i¢ed Rodnan TSS was derived by summation of the scores from all 17
areas. The pulsatility index is a parameter for renal vascular resistance de-
termined by color-£ow Doppler ultrasonography of the renal interlobar
arteries of both kidneys. The extent of lung ¢brosis was evaluated by a
pulmonary function test, including %DLco and %VC.
Figure 3. The presence of IgG anti-MMP-1 antibody in sera from
patients with SSc was con¢rmed by immunoblotting. Representative
immunoblotting of human recombinant MMP-1 with sera from patients
or a normal control is shown. Lane 1, colloidal gold-stained MMP-1; lanes
2^4, serum samples from patients with SSc positive for IgG anti-MMP-1
antibody by ELISA; lane 5, a serum sample from the SSc patient positive
for anti-topoisomerase I antibody, but not for IgG anti-MMP-1 antibody
by ELISA; and lane 6, a normal human serum. Markers for molecular
weights (kDa) are shown to the left. The results represent those obtained
with 10 SSc positive for IgG anti-MMP-1 antibody by ELISA, nine SSc
patients positive for either anti-topoisomerase I antibody, anti-centromere
antibody, or anti-U1RNP antibody, but not for IgG anti-MMP-1 antibody
by ELISA, and six healthy individuals.
Figure 4. IgG anti-MMP-1 antibody from patients with SSc inhib-
ited MMP-1 collagenase activity. IgG was puri¢ed from serum samples
of SSc patients positive for IgG anti-MMP-1 antibody by ELISA [anti-
MMP-1(þ )], those positive for either anti-topoisomerase I antibody,
anti-centromere antibody, or anti-U1RNP antibody, but not for IgG anti-
MMP-1 antibody by ELISA [anti-MMP-1 (^)], and normal control. Puri-
¢ed IgG was incubated with MMP-1 activated by p-aminophenylmercuric
acetate and MMP-1 collagenase activity was determined using biotinylated
bovine native collagen as substrate. The amount of cleaved biotinylated
fragments of collagen by MMP-1was measured by ELISA using a biotin-
binding microtiter plate. MMP-1 enzymatic activity is shown as a percen-
tage of p-aminophenylmercuric acetate-activated MMP-1 that was de¢ned
as 100% (activated MMP-1). Each histogram shows the mean (7SD)
results obtained for 10 persons of each group.
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DISCUSSION
In this study, ELISA revealed that IgG anti-MMP-1 autoantibody
levels were signi¢cantly elevated in sera from patients with SSc
relative to normal controls (Fig 1). Anti-MMP-1 autoantibody
levels were associated with a more severe form of SSc as IgG
anti-MMP-1 antibody levels were signi¢cantly higher in dSSc pa-
tients than those found in lSSc patients (Fig 1). Consistent
with this ¢nding, IgG anti-MMP-1 antibody levels signi¢cantly
correlated with the extent of ¢brosis in the skin, lung, and renal
blood vessels (Fig 2). Furthermore, elevated levels of anti-MMP-
1 autoantibody were speci¢c for patients with SSc as anti-MMP-1
antibody levels in patients with active SLE or dermatomyositis
were similar to those in normal controls (Fig 1). The presence of
anti-MMP-1 antibody in sera from patients with SSc was also
con¢rmed by immunoblotting analysis (Fig 3). Remarkably,
IgG anti-MMP-1 antibody in sera from SSc patients inhibited
MMP-1 collagenase activity (Fig 4). Collectively, the results
of this study suggest that anti-MMP-1 autoantibody contributes
to the development of ¢brosis by inhibiting MMP-1 collagenase
activity and reducing the turnover of the ECM.
The presence of autoantibodies is a central feature of SSc as
speci¢c autoantibodies are detected in more than 90% of patients
(Okano, 1996). In addition, anti-topoisomerase I antibody levels
closely correlate with disease activity and severity in SSc (Sato
et al, 2001); however, the pathogenic relationship between sys-
temic autoimmunity and the clinical manifestations of SSc,
including skin and visceral ¢brosis, remains unknown as
autoantigens are generally intracellular components critical for
cell mitosis and autoantibodies are not thought to contribute to
tissue damage in SSc (Okano, 1996). This study suggests that sys-
temic autoimmunity is linked to the development of ¢brosis
through the production of anti-MMP-1 antibody in SSc. Consis-
tently, critical roles of pathogenic autoantibodies in disease ex-
pression have been demonstrated in a murine model of systemic
autoimmunity: arthritis is provoked in healthy animals that re-
ceived arthritogenic autoantibody from K/BxN mice, a model
for human rheumatoid arthritis (Korganow et al, 1999; Matsumoto
et al, 2002). In addition, a recent study has shown that the pre-
sence of anti-¢brillin 1 autoantibodies in SSc may be the link
between ¢brosis and systemic autoimmunity as normal ¢bro-
blasts treated with anti-¢brillin 1 antibodies display an activated
phenotype overexpressing ¢brillin 1 as well as some other ECM
components.1 Furthermore, we have recently reported that the
elimination of autoantibody production results in decreased skin
¢brosis in a tight-skin mouse, a genetic model for human SSc
(Saito et al, 2002). Taken together, the presence of anti-MMP-1
autoantibody may be a clue for a role of systemic autoimmunity
in the disease expression of SSc.
Although anti-MMP-1 autoantibody was detected in 75% of
patients with dSSc, it was found only in 30% of patients with
lSSc (Fig 1,Table I). This ¢nding suggests that these autoantibo-
dies deteriorate or develop the ¢brosis rather than initiate the ¢-
brosis. Although early studies reported decreased production of
MMP-1 and MMP-3 by SSc ¢broblasts (Bou Gharios et al, 1994;
Takeda et al, 1994), recent studies of ¢broblasts from patients with
early dSSc (disease durationo 1y) have shown that mRNA levels
of MMP-1 and MMP-3 increase relative to normal ¢broblasts
(Kuroda and Shinkai, 1997). Consistently, recent cDNA microar-
ray studies of dermal ¢broblasts have shown increased levels of
MMP-1 transcripts in SSc ¢broblasts compared with control ¢-
broblasts.2 This augmented expression of MMP-1 is not due to
the promoter single nucleotide polymorphism, but to secondary
factors, such as cytokines or growth factors, including transform-
ing growth factor-b and interleukin-1b, or other post-transcrip-
tional events (Johnson et al, 2001). Therefore, as SSc has distinct
autoimmune background, it is possible that the upregulation of
MMP-1 expression in the early phase of dSSc induces anti-
MMP-1 autoantibodies that may contribute to the development
of ¢brosis.
Important roles of TIMP in the pathogenesis of ¢brosis have
been suggested. Speci¢cally, ¢broblasts from SSc patients express
elevated mRNA levels of TIMP-1, TIMP-2, and TIMP-3 (Kirk
et al, 1995; Kikuchi et al, 1997; Kuroda and Shinkai, 1997; Mattila
et al, 1998). In addition, patients with SSc exhibit elevated serum
levels of TIMP-1 and TIMP-2 that correlate with the extent of
skin sclerosis and lung ¢brosis (Kikuchi et al, 1995; Yazawa et al,
2000). Like TIMP, IgG anti-MMP-1 antibody levels correlated
with the extent of skin sclerosis, lung ¢brosis, and vascular da-
mage (Fig 2). Furthermore, IgG, but not IgM, anti-MMP-1 anti-
body was able to inhibit MMP-1 collagenase activity (Fig 4, and
data not shown).Therefore, it is likely that IgG anti-MMP-1 anti-
body and TIMP cooperatively inhibit collagenase activity, which
may result in the accumulation of ECM in SSc. The role of re-
duced type I collagen turnover by MMP inhibitors in the devel-
opment of skin ¢brosis is further supported by studies with
transgenic mice in which the collagenase cleavage site in type I
collagen is mutated rendering type I collagen resistant to cleavage
by collagenase (Liu et al, 1995). These transgenic mice developed
marked dermal ¢brosis similar to human SSc (Liu et al, 1995). In
addition to roles of MMP in the turnover of ECM, MMP are
clearly implicated in angiogenesis as MMP inhibitors reduce an-
giogenic responses both in vitro and in vivo (Stetler-Stevenson,
1999).Vascular damage that results in scleroderma renal crisis and
digital ulceration is an important manifestation in SSc. Anti-
MMP-1 antibody may also contribute to SSc vasculopathy
through inhibition of angiogenesis as well as vascular damage
due to ¢brosis. Thus, anti-MMP-1 antibody may be related to
various aspects of SSc disease expression, including skin sclerosis,
lung ¢brosis, vasculopathy, and autoimmunity. In addition, IgG
anti-MMP-1 antibody may be a useful, serologic marker for dSSc
as they were detected in 75% of dSSc patients, whereas they
were negative in 85% of lSSc patients. Collectively, the results
of this study suggest that MMP inhibitors, including anti-
MMP-1 antibody, would be potential therapeutic targets for SSc.
We thank Ms M. Matsubara for technical assistance.
REFERENCES
Bohan A, Peter JB: Polymyositis and dermatomyositis (¢rst of two parts). N Engl J
Med 292:344^348, 1975a
Bohan A, Peter JB: Polymyositis and dermatomyositis (second of two parts). N Eng J
Med 292:403^407, 1975b
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: the Committee
on Prognosis Studies in SLE: Derivation of the SLEDAI. a disease activity in-
dex for lupus patients. Arthritis Rheum 35:630^640, 1992
Bou Gharios G, Osman J, Black C, Olsen I: Excess matrix accumulation in sclero-
derma is caused partly by di¡erential regulation of stromelysin and TIMP-1
synthesis. Clin Chem Acta 231:69^78, 1994
Clements PJ, Lachenbruch PA, Seibold JR, et al: Skin thickness score in systemic
sclerosis: an assessment of interobserver variability in 3 independent studies.
J Rheumatol 20:1892^1896, 1993
Gomez DE, Alonso DF,Yoshiji H,Thorgeirsson UP:Tissue inhibitors of metallopro-
teinases: structure, regulation and biological functions. Eur J Cell Biol 74:111^
122, 1997
Jimenez SA, Hitraya E, Varga J: Pathogenesis of scleroderma: Collagen. Rheum Dis
Clin North Am 22:647^674, 1996
Johnson RW, Reveille JD, McNearney T, et al: Lack of association of a functionally
relevant single nucleotide polymorphism of matrix metalloproteinase-1 pro-
moter with systemic sclerosis (scleroderma). Genes Immun 2:273^275, 2001
K<h<ri VM, Saarialho-Kere U: Matrix metalloproteinases in skin. Exp Dermatol
6:199^213, 1997
Kikuchi K, Kubo M, Sato S, Fujimoto M, Tamaki K: Serum tissue inhibitor of
metalloproteinases in patients with systemic sclerosis. J Am Acad Dermatol 33:
973^978, 1995
1Zhou X,Tan FK, Bona CA,Wallis D, Milewicz DM, Arnett FC: Anti-
¢brillin-1 autoantibodies induce increased gene expression of FBN1 in
normal dermal ¢broblasts. Arthritis Rheum 44 (Suppl.):S194, 2001 (Abstr.)
2Xiaodong Z,Tan FK, Xiong M, Milewicz DM, Arnett FC: Compari-
sons of ¢broblasts gene expression pro¢les in systemic sclerosis, normal
controls, scleromyxedema, and eosinophilic fasciitis. Arthritis Rheum 41
(Suppl.):S259, 2000 (Abstr.)
546 SATO ETAL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
Kikuchi K, Kadono T, Furue M, Tamaki K: Tissue inhibitor of metalloproteinase
1 (TIMP-1) may be an autocrine growth factor in scleroderma ¢broblasts.
J Invest Dermatol 108:281^284, 1997
Kirk TZ, Mark ME, Chua CC, Chua BH, Mayes MD: Myo¢broblasts from sclero-
derma skin synthesize elevated levels of collagen and tissue inhibitor of
metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem
270:3423^3428, 1995
KorganowAS, Ji H, Mangialaio S, et al: From systemic T cell self-reactivity to organ-
speci¢c autoimmune disease via immunoglobulins. Immunity 10:451^461, 1999
Kuroda K, Shinkai H: Gene expression of types I and III collagen, decorin, matrix
metalloproteinases and tissue inhibitors of metalloproteinases in skin ¢bro-
blasts from patients with systemic sclerosis. Arch Dermatol Res 289:567^572, 1997
LeRoy EC: Increased collagen synthesis by scleroderma skin ¢broblasts in vitro:
A possible defect in the regulation or activation of the scleroderma ¢broblast.
J Clin Invest 54:880^889, 1974
LeRoy EC, Krieg T, Black C, et al: Scleroderma (systemic sclerosis): Classi¢cation,
subsets, and pathogenesis. J Rheumatol 15:202^205, 1988
Liu X,Wu H, Byrne M, Je¡rey J, Krane S, Jaenisch R: A targeted mutation at the
known collagenase cleavage site in mouse type I collagen impairs tissue remo-
deling. J Cell Biol 130:227^237, 1995
Lovell CR, Nicholls AC, DuanceVC, BaileyAJ: Characterization of dermal collagen
in systemic sclerosis. Br J Dermatol 100:359^369, 1979
Matsumoto I, Maccioni M, Lee DM, et al: How antibodies to a ubiquitous cytoplas-
mic enzyme may provoke joint-speci¢c autoimmune disease. Nat Immunol
3:360^365, 2002
Mattila L, Airola K, Ahonen M, Hietarinta M, Black C, Saarialho-Kere U,
K<h<ri VM: Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3)
mRNA expression in scleroderma skin ¢broblasts. J Invest Dermatol 110:416^
421, 1998
Nagase H,Woessner JF Jr: Matrix metalloproteinases. J Biol Chem 274:21491^21494,
1999
Nishijima C, Sato S, Hasegawa M, Nagaoka T, Hirata A, Komatsu K, Takehara K:
Renal vascular damage in Japanese patients with systemic sclerosis. Rheumatol-
ogy 40:406^109, 2001
OkanoY: Anti-nuclear antibody in systemic sclerosis (scleroderma). Rheum Dis Clin
North Am 22:709^735, 1996
Saito E, Fujimoto M, Hasegawa M, et al: CD19-dependent B lymphocyte signaling
thresholds in£uence skin ¢brosis and autoimmunity in the tight-skin mouse.
J Clin Invest 109:1453^1462, 2002
Sato S: Abnormalities of adhesion molecules and chemokines in scleroderma. Curr
Opin Rheumatol 11:503^507, 1999
Sato S, Ihn H, Kikuchi K, Takehara K: Antihistone antibodies in systemic sclerosis:
Association with pulmonary ¢brosis. Arthritis Rheum 37:391^394, 1994
Sato S, Hasegawa M, Fujimoto M,Tedder TF,Takehara K: Quantitative genetic var-
iation in CD19 expression correlates with autoimmunity. J Immunol 165:6635^
6643, 2000
Sato S, Hamaguchi Y, Hasegawa M,Takehara K: Clinical signi¢cance of anti-topoi-
somerase I antibody levels by ELISA in systemic sclerosis. Rheumatology
40:1135^1140, 2001
Silver RM: Clinical problems:The lungs. Rheum Dis Clin North Am 22:825^840, 1996
Steen VD, Powell DL, Medsger TAJ: Clinical correlations and prognosis based on
serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum
31:196^203, 1988
Stetler-StevensonWG: Matrix metalloproteinases in angiogenesis: A moving target
for therapeutic intervention. J Clin Invest 103:1237^1241, 1999
Subcommittee for Scleroderma Criteria of the American Rheumatism Association
Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the
classi¢cation of systemic sclerosis (scleroderma). Arthritis Rheum 23:581^590, 1980
Takeda K, Hatamochi A, Ueki H, Nakata M, Oishi Y: Decreased collagenase
expression in cultured systemic sclerosis ¢broblasts. J Invest Dermatol 103:359^
363, 1994
Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classi¢cation of
systemic lupus erythematosus. Arthritis Rheum 25:1271^1277, 1982
Warshauer DM,Taylor KJW, Bia MJ, et al: Unusual causes of increased vascular im-
pedance in renal transplants: Duplex doppler evaluation. Radiology 169:367^370,
1988
Yazawa N, Kikuchi K, Ihn H, Fujimoto M, Kubo M, Tamaki T, Tamaki K: Serum
levels of tissue inhibitor of metalloproteinases 2 in patients with systemic
sclerosis. J Am Acad Dermatol 42:70^75, 2000
Young-Min SA, Beeton C, Laughton R, et al: SerumTIMP-1,TIMP-2, and MMP-1
in patients with systemic sclerosis, primary Raynaud’s phenomenon, and in
normal controls. Ann Rheum Dis 60:846^851, 2001
ANTI-MMP-1 AUTOANTIBODY IN SSC 547VOL. 120, NO. 4 APRIL 2003
